Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]


On page 215, please note correspondence should have been listed as:
Roshni Menon,
D II/17, JIPMER Campus, Dhanvanthri Nagar,
Pondicherry, India 605006
Tel +91 944 320 8140
Email roshnijagdish@gmail.com

On page 215, the first sentence of the Introduction was “Psoriasis is a chronic inflammatory disease of the skin characterized by exacerbations and remissions affecting 1%–3% of the world’s population, and approximately 20% of patients have moderate to severe disease.”1,2 However should have been “Psoriasis is a chronic inflammatory disease of the skin characterized by exacerbations and remissions affecting 1%–3% of the world’s population. Approximately 20% of patients have moderate to severe disease.”1,2

On page 217, 219, and 221 the running header was “Itolizumab – a CD6 monoclonal antibody for the treatment of psoriasis” however should have been “Itolizumab – a humanized anti CD6 monoclonal antibody for the treatment of psoriasis”.

On page 218, Table 1, the second column heading was listed as “Anand et al25 n=40 (moderate–severe psoriasis)” however should have been “Anand et al25 n=40/32 weeks (moderate–severe psoriasis)”. 

For personal use only
Powered by TCPDF (www.tcpdf.org)